This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Non-Nicotine Agents for Smoking Cessation

This study has been completed.
Information provided by:
VA Office of Research and Development Identifier:
First received: April 15, 2005
Last updated: April 2, 2008
Last verified: October 2006
The primary objective of this study is to determine which is the better approach to smoking cessation in veterans: bupropion combined with transdermal nicotine or high dose nicotine replacement therapy (NRT) using transdermal nicotine combined with nicotine inhaler.

Condition Intervention Phase
Tobacco Use Disorder Drug: bupropion and transdermal patch Drug: transdermal patch and nicotine inhaler Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Open Label
Primary Purpose: Treatment
Official Title: Non-Nicotine Agents for Smoking Cessation

Resource links provided by NLM:

Further study details as provided by VA Office of Research and Development:

Study Start Date: October 2003
Estimated Study Completion Date: September 2005
Detailed Description:
This study is a two-arm open-label, randomized controlled trial of bupropion combined with transdermal nicotine versus high dose NRT (transdermal nicotine and nicotine inhaler) with all subjects receiving a behavioral counseling program for smoking cessation.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Readiness to set a quit date in the next two weeks,
  • Current smoking of at least 15 cigarettes a day

Exclusion Criteria:

  • Current untreated depression or receiving treatment for depression,
  • History of seizures, major head injury, or other predisposition for seizures
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00108537

United States, Colorado
Denver VA Medical Center
Denver, Colorado, United States, 80220
Sponsors and Collaborators
VA Office of Research and Development
  More Information Identifier: NCT00108537     History of Changes
Other Study ID Numbers: ADRD-013-01S
Study First Received: April 15, 2005
Last Updated: April 2, 2008

Keywords provided by VA Office of Research and Development:
drug therapy
smoking cessation

Additional relevant MeSH terms:
Tobacco Use Disorder
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Ganglionic Stimulants
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Dopamine Agents
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors processed this record on June 23, 2017